echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Amino Acids Research > Meihua Biotech Group Co., Ltd. plans to issue shares to purchase assets and postpone the resumption of trading announcement

    Meihua Biotech Group Co., Ltd. plans to issue shares to purchase assets and postpone the resumption of trading announcement

    • Last Update: 2020-06-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Securities Code: 600873 Securities Short: Plum Bio (600873, stock bar) Announcement No.: 2014-056H58Meihua Biotech Group Co., Ltdplans to issue shares to purchase assets and postpone the resumption of trading noticeH58's Board of Directors and all directors to ensure that the contents of this announcement are free of false, misleading or material omissions, and bear individual liability for the authenticity, accuracy and completeness of the contents of this announcementH58
    The shares of Meihua Biotech Group Co., Ltd("Company" and "Listed Company") were suspended from trading on August 26, 2014 due to the planning of the issuance of shares to purchase assetsSubsequently, on September 2, 2014, September 10, 2014, September 17, 2014, september 24, 2014, the Company issued the "Continued Suspension of Trading Notices on Significant Matters" (Notice Nos2014-045, 2014-046, 2014-047, 2014-048)Due to the large number of shareholders involved in the subject matter of the transaction, some shareholders are required to perform the necessary internal approval procedures, and the transaction related parties on the specific matters of the transaction plan still need to continue in-depth consultation to determine, September 30, 2014 the company issued "on the planning of the issuance of shares to purchase assets and extended the resumption of trading announcement" (announcement number: 2014-049)Subsequently, in accordance with the disclosure requirements, on October 14, 2014, October 21, 2014 and October 28, 2014, the Company issued the "Progress Announcement on the Suspension of The Issue of Shares Purchased Assets" (Announcement No2014-050, 2014-051, 2014-055)H58
      After consultation with the parties to the transaction, the proposed transaction plan is: the company intends to acquire a biofermentation enterprise in the industry by issuing shares and cash payment, and to raise supporting funds for the non-public issuance of shares by no more than 10 specific investors The total amount of funds raised shall not exceed 25% of the total transaction amount, and the funds raised shall be used to pay the cash consideration of the assets under purchase and the construction and working capital arrangements for a project of the underlying assets, and shall not be used to supplement the working capital of the listed company H58
      The asset is a production and sales of amino acids, MSG, compound fertilizer and corn by-products for the main business of enterprises As of December 31, 2013, the total assets of the enterprise were about 6 billion yuan, with net assets of about 1.9 billion yuan The underlying asset is estimated at about $3.8 billion H58
      During the suspension period, the Company engaged independent financial advisers, legal advisers, auditanding and asset assessment intermediaries to conduct due diligence, audit, evaluation and other work on asset purchases H58
      Since the suspension, the Company and the parties concerned have actively promoted due diligence, auditing, evaluation and business negotiations on the purchase of assets in this offering of shares Due to the large number of shareholders in the underlying assets, some shareholders are required to perform the necessary internal approval procedures, and the parties to the transaction on the transaction target performance commitment, payment methods, transaction plans and other aspects of further in-depth consultations, in order to finalize the transaction plan As a result, the Company is not expected to disclose the prospect or report on the issuance of shares and resume trading by October 30, as originally planned H58
      In view of this, in order to protect the interests of investors, upon application, the Company's shares will continue to be suspended for no more than 30 days from October 30, 2014 During the suspension period, the Company and relevant parties will accelerate the process of this transaction, and will fulfill the obligation of information disclosure in a timely manner in accordance with the progress, issue the progress of the relevant matters every five trading days, pending the completion of the relevant work to convene the board of directors to consider the plan or report, timely announcement and re-listing H58
      If the Company fails to disclose the plan or report for the purchase of assets of the shares issued within the above-mentioned extension period, the Company shall, in accordance with the actual situation, determine whether to apply to the Shanghai Stock Exchange for an extension of the re-listing If the Company has not submitted an application for extension of re-listing or an application for extension of re-listing has not been approved by the Shanghai Stock Exchange, the Company shall resume trading on November 28, 2014, and the Company undertakes not to plan to issue shares to purchase assets within six months from the date of the resumption of trading of the Company H58
      This announcement is hereby made H58
      Meihua Biotech Group Co., Ltd H58 October 29, 2014 H58 Securities Code: 600873 Securities Short: Meihua Bio (600873, share bar) Announcement No: 2014-0 56 H58 Meihua Biotech Group Co., Ltd plans to issue shares to purchase assets and postpone the resumption of trading announcement
    H58 's Board of Directors and all directors to ensure that there are no false records, misleading statements or material omissions in the contents of this announcement, and bear individual and joint liability for the authenticity, accuracy and completeness of its contents H58
      The shares of Meihua Biotech Group Co., Ltd ("Company" and "Listed Company") were suspended from trading on August 26, 2014 due to the planning of the issuance of shares to purchase assets Subsequently, on September 2, 2014, September 10, 2014, September 17, 2014, september 24, 2014, the Company issued the "Continued Suspension of Trading Notices on Significant Matters" (Notice Nos 2014-045, 2014-046, 2014-047, 2014-048) Due to the large number of shareholders involved in the subject matter of the transaction, some shareholders are required to perform the necessary internal approval procedures, and the transaction related parties on the specific matters of the transaction plan still need to continue in-depth consultation to determine, September 30, 2014 the company issued "on the planning of the issuance of shares to purchase assets and extended the resumption of trading announcement" (announcement number: 2014-049) Subsequently, in accordance with the disclosure requirements, on October 14, 2014, October 21, 2014 and October 28, 2014, the Company issued the "Progress Announcement on the Suspension of The Issue of Shares Purchased Assets" (Announcement No 2014-050, 2014-051, 2014-055) H58
      After consultation with the parties to the transaction, the proposed transaction plan is: the company intends to acquire a biofermentation enterprise in the industry by issuing shares and cash payment, and to raise supporting funds for the non-public issuance of shares by no more than 10 specific investors The total amount of funds raised shall not exceed 25% of the total transaction amount, and the funds raised shall be used to pay the cash consideration of the assets under purchase and the construction and working capital arrangements for a project of the underlying assets, and shall not be used to supplement the working capital of the listed company H58
      The asset is a production and sales of amino acids, MSG, compound fertilizer and corn by-products for the main business of enterprises As of December 31, 2013, the total assets of the enterprise were about 6 billion yuan, with net assets of about 1.9 billion yuan The underlying asset is estimated at about $3.8 billion H58
      During the suspension period, the Company engaged independent financial advisers, legal advisers, auditanding and asset assessment intermediaries to conduct due diligence, audit, evaluation and other work on asset purchases H58
      Since the suspension, the Company and the parties concerned have actively promoted due diligence, auditing, evaluation and business negotiations on the purchase of assets in this offering of shares Due to the large number of shareholders in the underlying assets, some shareholders are required to perform the necessary internal approval procedures, and the parties to the transaction on the transaction target performance commitment, payment methods, transaction plans and other aspects of further in-depth consultations, in order to finalize the transaction plan As a result, the Company is not expected to disclose the prospect or report on the issuance of shares and resume trading by October 30, as originally planned H58
      In view of this, in order to protect the interests of investors, upon application, the Company's shares will continue to be suspended for no more than 30 days from October 30, 2014 During the suspension period, the Company and relevant parties will accelerate the process of this transaction, and will fulfill the obligation of information disclosure in a timely manner in accordance with the progress, issue the progress of the relevant matters every five trading days, pending the completion of the relevant work to convene the board of directors to consider the plan or report, timely announcement and re-listing H58
      If the Company fails to disclose the plan or report for the purchase of assets of the shares issued within the above-mentioned extension period, the Company shall, in accordance with the actual situation, determine whether to apply to the Shanghai Stock Exchange for an extension of the re-listing If the Company has not submitted an application for extension of re-listing or an application for extension of re-listing has not been approved by the Shanghai Stock Exchange, the Company shall resume trading on November 28, 2014, and the Company undertakes not to plan to issue shares to purchase assets within six months from the date of the resumption of trading of the Company H58
      This announcement is hereby made H58
      Meihua Biotech Group Co., Ltd H58 on October 29, 2014 The of H58 shared to the feed
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.